OB 318
Alternative Names: OB-318Latest Information Update: 28 Aug 2024
At a glance
- Originator Oneness Biotech
- Class Anti-inflammatories; Antineoplastics; Herbal medicines; Traditional Chinese medicine
- Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; MTOR protein inhibitors; Proto-oncogene protein c-akt inhibitors; Vascular endothelial growth factor A inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Liver cancer
Most Recent Events
- 28 Aug 2024 No recent reports of development identified for phase-I development in Liver-cancer in Taiwan (PO)
- 23 Aug 2022 Phase I development is ongoing in Taiwan (NCT02347228) (MICROBIO Group pipeline, August 2022)
- 28 Jun 2022 No recent reports of development identified for phase-I development in Liver-cancer in Taiwan (PO)